REMINDER: Our user survey closes on Friday, please submit your responses here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFrontier Ip Regulatory News (FIPP)

Share Price Information for Frontier Ip (FIPP)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 41.50
Bid: 40.00
Ask: 43.00
Change: 0.50 (1.22%)
Spread: 3.00 (7.50%)
Open: 41.50
High: 41.50
Low: 41.50
Prev. Close: 41.00
FIPP Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Exercise of Options & Total Voting Rights

14 Sep 2023 07:00

RNS Number : 3747M
Frontier IP Group plc
14 September 2023
 

AIM: FIPP

14 September 2023

 

Frontier IP Group Plc

("Frontier IP" or the "Group")

 

Exercise of Options, Issue of Equity

and

Total Voting Rights

 

Frontier IP, a specialist in commercialising intellectual property, announces that it has issued and allotted 47,000 ordinary shares of 10 pence each in the Group (the "New Ordinary Shares") following an exercise of 47,000 options on 13 September 2023. The options have been exercised as follows:

 

Grant Date

Number of Options

Exercise Price

11 May 2017

47,000

40 pence

 

The New Ordinary Shares have been issued pursuant to the exercise of options granted to an employee under the Frontier IP Group plc Employee Share Option Scheme 2011. The New Ordinary Shares rank, pari passu, in all respects with the Company's existing ordinary shares of 10p each ("Ordinary Shares"). 

 

Application has been made to the London Stock Exchange for the New Ordinary Shares to be admitted to trading on AIM. It is expected that admission of the 47,000 New Ordinary Shares to trading on AIM will become effective on, or around, 21 September 2023 ("Admission").

 

Total Voting Rights

Following Admission, the issued share capital of the Company will consist of 55,734,553 Ordinary Shares, with one voting right per share. The Company does not hold any Ordinary Shares in treasury. Therefore, the total number of Ordinary Shares and voting rights in the Company will be 55,734,553. From Admission, this figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.

 

 

ENQUIRIES

 

Frontier IP Group Plc

T: 020 3968 7815

Neil Crabb, Chief Executive

Andrew Johnson, Communications & Investor Relations

Company website: www.frontierip.co.uk

 

neil@frontierip.co.uk

M: 07464 546 025

Allenby Capital Limited (Nominated Adviser)

Nick Athanas / George Payne

 

T: 0203 328 5656

Singer Capital Markets (Broker)

Harry Gooden / James Fischer

 

 

T: 0207 496 3000

 

ABOUT FRONTIER IP

Frontier IP unites science and commerce by identifying strong intellectual property and accelerating its development through a range of commercialisation services. A critical part of the Group's work is involving relevant industry partners at an early stage of development to ensure technology meets real world demands and needs.

 

The Group looks to build and grow a portfolio of equity stakes and licence income by taking an active involvement in spin-out companies, including support for fund raising and collaboration with relevant industry partners at an early stage of development.

 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCGPUGWBUPWGMW
Date   Source Headline
6th Dec 20196:25 pmRNSHolding(s) in Company
5th Dec 201912:00 pmRNSHolding(s) in Company
4th Dec 201912:00 pmRNSResult of AGM & Total Voting Rights
26th Nov 201912:58 pmRNSHolding(s) in Company
13th Nov 20195:00 pmRNSPosting of Annual Report and Accounts
7th Nov 201912:20 pmRNSHolding(s) in Company
6th Nov 20192:00 pmRNSResult of Placing
6th Nov 20197:01 amRNSProposed fundraising of £3.5m by way of Placing
6th Nov 20197:00 amRNSFinal Results
22nd Oct 20197:00 amRNSAppointment of senior advisers
15th Oct 20197:00 amRNSNew portfolio company: Elute Intelligence Holdings
10th Sep 20197:00 amRNSAppointment of Broker
25th Jul 20197:00 amRNSExscientia collaboration with Rallybio
15th Jul 201912:08 pmRNSHolding(s) in Company
14th Jun 20197:00 amRNSExscientia partnership with GT Apeiron
31st May 20195:00 pmRNSTotal Voting Rights
31st May 20193:15 pmRNSDirectorate Change
28th May 20197:00 amRNSFieldwork Robotics completes initial field trials
15th May 20197:00 amRNSDirector exercise of options, shareholding and TVR
10th May 201911:48 amRNSHolding(s) in Company
30th Apr 20197:00 amRNSEuropean plan to boost marine & coastal economies
8th Apr 20197:00 amRNSParkside Architectural Tiles launch Alusid range
8th Apr 20197:00 amRNSBosch UK to work with Pulsiv Solar
8th Apr 20197:00 amRNSInvestor event at the Royal Academy of Engineering
4th Apr 20197:00 amRNSExscientia reaches first major milestone with GSK
3rd Apr 20195:51 pmRNSHolding(s) in Company
3rd Apr 20193:45 pmRNSHolding(s) in Company
1st Apr 20197:00 amRNSFieldwork Robotics wins Innovate UK ISCF grant
27th Mar 20191:30 pmRNSHolding(s) in Company
27th Mar 20191:30 pmRNSHolding(s) in Company
27th Mar 20197:00 amRNSBoard Appointment
27th Mar 20197:00 amRNSUnaudited Half Year Results
21st Mar 20199:18 amRNSTrading Update
21st Mar 20199:14 amRNSExscientia & Celgene drug discovery collaboration
6th Mar 20195:15 pmRNSHolding(s) in Company
20th Feb 20197:00 amRNSTVG - key partner in $9.67m DARPA project award
12th Feb 20197:00 amRNSThird Portuguese spin out: Insignals Neurotech
4th Feb 20197:00 amRNSAmprologix wins DHSC backing for new antibiotic
31st Jan 20199:00 amRNSNandi Proteins led consortium wins UK grant
25th Jan 20197:00 amRNSThe Vaccine Group wins Department of Health grant
7th Jan 20191:29 pmRNSExscientia Series B funding & Roche collaboration
27th Dec 20187:00 amRNSMolendotech - Palintest start commercial roll out
19th Dec 201811:45 amRNSResult of AGM
30th Nov 20185:30 pmRNSTotal Voting Rights
23rd Nov 201812:10 pmRNSPosting of Annual Report and Notice of AGM
22nd Nov 20181:12 pmRNSHolding(s) in Company
22nd Nov 201810:36 amRNSHolding(s) in Company
21st Nov 20183:30 pmRNSHolding(s) in Company
21st Nov 201811:00 amRNSTotal Voting Rights and Director/PDMR Shareholding
15th Nov 20184:08 pmRNSDirector Dealing

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.